Clinical trial

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

NCT07150962

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-10-15

PhasePHASE1

Study timeline

Study start (actual)2025-10-15Date precision: day

Registry last updated2025-11-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Overweight or Obesityunresolved

Interventions

HRS-9531 TabletDRUG

Sponsors & collaborators

Fujian Shengdi Pharmaceutical Co., Ltd.lead sponsor

Mapped research locations

HefeiAnhui, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07150962 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.